A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cisplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 27 May 2013 Biomarkers information updated
- 12 May 2009 Actual end date (October 2007) added as reported by ClinicalTrials.gov.
- 01 Oct 2007 Status changed from in progress to completed.